Creo Medical Group plc has completed a US$15.7 million equity fundraise
October 2024 — Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Creo Medical develops minimally invasive electrosurgical devices designed to improve patient outcomes. With its innovative CROMA and Kamaptive technologies, Creo Medical is setting new standards in precision and flexibility for clinicians across a range of surgical procedures. This funding has been sought to mitigate the completion risk of its recently announced sale of a 51% controlling interest in the group’s European subsidiary, Creo Medical Europe. It also aims to provide balance sheet strength for future growth, as Creo Medical continues to roll out its defined medtech strategy.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, served as advisor to Creo Medical on the transaction.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more